Last reviewed · How we verify
ZYDENA TAB.75mg(Udenafil 75mg)
Udenafil inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cyclic GMP levels to promote smooth muscle relaxation and penile erection.
Udenafil inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cyclic GMP levels to promote smooth muscle relaxation and penile erection. Used for Erectile dysfunction.
At a glance
| Generic name | ZYDENA TAB.75mg(Udenafil 75mg) |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Phosphodiesterase type 5 (PDE5) inhibitor |
| Target | PDE5 (phosphodiesterase type 5) |
| Modality | Small molecule |
| Therapeutic area | Urology / Sexual Health |
| Phase | FDA-approved |
Mechanism of action
As a PDE5 inhibitor, udenafil prevents the breakdown of cyclic guanosine monophosphate (cGMP), allowing sustained smooth muscle relaxation in penile tissue. This enhances blood flow to the corpus cavernosum in response to sexual stimulation, facilitating erectile function. Udenafil has a longer half-life compared to some other PDE5 inhibitors, providing extended therapeutic duration.
Approved indications
- Erectile dysfunction
Common side effects
- Headache
- Flushing
- Dyspepsia
- Nasal congestion
- Back pain
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZYDENA TAB.75mg(Udenafil 75mg) CI brief — competitive landscape report
- ZYDENA TAB.75mg(Udenafil 75mg) updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI